AndreaBozzo/ceres-open-data-index huggingface dataset:
MD COVID-19 - Probable Deaths by Gender Distribution

<b>Note:</b> Starting April 27, 2023 updates change from daily to weekly.

<b>Summary</b>
The cumulative number of probable COVID-19 deaths among Maryland residents by gender: Female; Male; Unknown.

<b>Description</b>
The MD COVID-19 - Probable Deaths by Gender Distribution data layer is a collection of the statewide confirmed and probable COVID-19 related deaths that have been reported each day by the Vital Statistics Administration by gender. A death is classified as probable if the person's death certificate notes COVID-19 to be a probable, suspect or presumed cause or condition. Probable deaths are not yet been confirmed by a laboratory test. Some data on deaths may be unavailable due to the time lag between the death, typically reported by a hospital or other facility, and the submission of the complete death certificate. Confirmed deaths are available from the MD COVID-19 - Confirmed Deaths by Gender Distribution data layer.

<b>Terms of Use</b>
The Spatial Data, and the information therein, (collectively the "Data") is provided "as is" without warranty of any kind, either expressed, implied, or statutory. The user assumes the entire risk as to quality and performance of the Data. No guarantee of accuracy is granted, nor is any responsibility for reliance thereon assumed. In no event shall the State of Maryland be liable for direct, indirect, incidental, consequential or special damages of any kind. The State of Maryland does not accept liability for any damages or misrepresentation caused by inaccuracies in the Data or as a result to changes to the Data, nor is there responsibility assumed to maintain the Data in any manner or form. The Data can be freely distributed as long as the metadata entry is not modified or deleted. Any data derived from the Data must acknowledge the State of Maryland in the metadata.
Verbal autopsy of 48 000 adult deaths attributable to medical causes in Chennai (formerly Madras), India

Background
          In the city of Chennai, India, registration of the fact of death is almost complete but the cause of death is often inadequately recorded on the death certificate. A special verbal autopsy (VA) study of 48 000 adult deaths in Chennai during 1995–97 was conducted to arrive at the probable underlying cause of death and to measure cause specific mortality rates for Chennai.
        
        
          Methods
          Trained non-medical graduates with at least 15 years of formal education interviewed the surviving family members or an associate of the deceased to write a report on the complaints, symptoms, signs, duration and treatment details of illness prior to death. Each report was reviewed centrally by two physicians independently. The reliability was assessed by comparing deaths attributed to cancer by VA with records in Vital Statistics Department and Chennai Cancer Registry.
        
        
          Results
          The VA reduced the proportion of deaths attributed to unspecified medical causes and unknown causes from 37% to 7% in early adult life and middle age (25–69 yrs) and has yielded fewer unspecified causes (only 10%) than the death certificate. The sensitivity of VA to identify cancer was 94% in the age group 25–69.
        
        
          Conclusion
          VA is practicable for deaths in early adult life or middle age and is of more limited value in old age. A systematic program of VA of a representative sample of deaths could assign broad causes not only to deaths in childhood (as has previously been established) but also to deaths in early adult life and middle age.
Dorzolamide hydrochloride

Dorzolamide Hydrochloride is a prescription eye drop solution that helps lower pressure inside the eye, commonly used to treat glaucoma or ocular hypertension. It works by inhibiting carbonic anhydrase, reducing fluid production in the eye. Available in 5 mL or 10 mL bottles, manufactured by Leading Pharma, LLC. This information was generated using AI and is provided for informational and research purposes only.
Treatment Episode Data Set (TEDS): 1993-1998, National Admissions to Substance Abuse Treatment Services

This report presents data from the Treatment Episode Data Set (TEDS) for 1998, and trend data for 1993 to 1998. The report provides information on the demographic and substance abuse characteristics of people aged 12 and older admitted to treatment for abuse of alcohol and/or drugs in facilities that report to individual state administrative data systems.
Respiratory syncytial virus and TNFalpha induction of chemokine gene expression involves differential activation of Rel A and NF-kappaB1

Background
          Respiratory syncytial virus (RSV) infection of airway epithelial cells stimulates the expression and secretion of a variety of cytokines including the chemotactic cytokines interleukin-8 (IL-8), monocyte chemoattractant protein-1 (MCP-1), and RANTES (regulated upon activation, normal T cell expressed and secreted). Chemokines are important chemoattractants for the recruitment of distinct sets of leukocytes to airway sites of inflammation.
        
        
          Results
          We have shown previously that chemokine expression is regulated in airway epithelial cells (A549) in a stimulus-specific manner in part through the redox-responsive transcription factors AP-1 and NF-κB. In this study, we examined the NF-κB-mediated effects of RSV and the proinflammatory cytokine TNFα on the induction of IL-8, MCP-1 and RANTES chemokine gene expression in A549 epithelial cells. The results demonstrate that RSV induces chemokine expression with distinct kinetics that is associated with a specific pattern of NF-κB binding activity. This distinction was further demonstrated by the differential effects of the NF-κB inhibitors dexamethasone (DEX) and N-acetyl-L-cysteine (NAC). NAC preferentially inhibited RSV induced chemokine expression, whereas DEX preferentially inhibited TNFα induced chemokine expression. DNA binding studies using NF-κB subunit specific binding ELISA demonstrated that RSV and TNFα induced different NF-κB binding complexes containing Rel A (p65) and NF-κB1 (p50). Both TNFα and RSV strongly induced Rel A the activation subunit of NF-κB, whereas only TNFα was able to substantially induce the p50 subunit. Consistent with the expression studies, RSV but not TNFα induction of Rel A and p50 were markedly inhibited by NAC, providing a mechanism by which TNFα and RSV can differentially activate chemokine gene expression via NF-κB.
        
        
          Conclusions
          These data suggest that RSV induction of chemokine gene expression, in contrast to TNFα, involves redox-sensitive NF-κB complexes containing predominantly Rel A.
Compound 526173: Dimethyl 4-bromophenyl phosphate

Chemical compound data from PubChem database. IUPAC Name: (4-bromophenyl) dimethyl phosphate. Molecular Formula: C8H10BrO4P. Molecular Weight: 281.04. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 525888: N,N-Dimethyl-N'-(4-methoxyphenyl)-isobutyramidine

Chemical compound data from PubChem database. IUPAC Name: N'-(4-methoxyphenyl)-N,N,2-trimethylpropanimidamide. Molecular Formula: C13H20N2O. Molecular Weight: 220.31. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E400487-T1: [Translated] CRUMBLE ELEMENT WITH GUIDE MECHANISM

A deformable element for a vehicle, particularly a rail vehicle, comprising a profiled part (CR) disposed between two end plates (AC, AP) and having the form of a tubular box, particularly of polygonal cross section for dissipating impact energy in the event of longitudinal compression by plastic deformation, and comprising a guide element (FH) disposed parallel to the longitudinal direction of said profiled part (CR), which guide element is fixed to the end plate (AC) remote from the vehicle and is capable of sliding through a through opening (DL) in the end plate (AP) facing the vehicle, wherein the end plate (AP) facing the vehicle has a through opening (DL) which has a shape which permits contactless sliding of said guide element (FH) in the longitudinal direction and lateral inclination of said guide element relative to the longitudinal direction.
Compound 527149: 1-Methyl-1-(4-methylphenyl)-3-(2-phenylpropan-2-yl)urea

Chemical compound data from PubChem database. IUPAC Name: 1-methyl-1-(4-methylphenyl)-3-(2-phenylpropan-2-yl)urea. Molecular Formula: C18H22N2O. Molecular Weight: 282.4. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Updating a systematic review – what difference did it make? Case study of nicotine replacement therapy

Aims
          To examine the effect of updating a systematic review of nicotine replacement therapy on its contents and conclusions.
        
        
          Methods
          We examined the effects of regular updating of a systematic review of nicotine replacement therapy for smoking cessation. We considered two outcomes. First, we assessed the effect of adding new data to meta-analyses, comparing results in 2000 with the results in 1994. Second, we assessed qualitatively the ways inwhich the nature of the questions addressed by the review had changed between the two dates. For the first outcome, we compared the number of trials, the pooled estimate of effect using the odds ratio, and the results of pre-specified subgroup analyses, for nicotine gum and patch separately. Using a test for interaction, we assessed whether differences between estimates were statistically significant.
        
        
          Results
          There were ten new trials of nicotine gum between 1994 and 2000, and the meta-analytic effect changed little. For the nicotine patch the number of trials increased from 9 to 30, and the meta-analytic effect fell from 2.07 (95% CI 1.64 – 2.62) to 1.73 (95% CI 1.56 – 1.93). Apparent differences in relative effect in sub-groups found in 1994 were not found in 2000. The updated systematic review addressed a number of questions not identified in the original version.
        
        
          Conclusions
          Updating the meta-analyses lead to a more precise estimate of the likely effect of the nicotine patch, but the clinical message was unchanged. Further placebo controlled NRT trials are not likely to add to the evidence base. It is questionable whether updating the meta-analyses to include them is worthwhile. The content of the systematic review has, however, changed, with the addition of data addressing questions not considered in the original review. There is a tension between the principle of identifying the important questions prior to conducting a review, and keeping the review up to date as primary research identifies new avenues of enquiry.
2015 National Directory of Mental Health Treatment Facilities

This publication is a National Directory of Mental Health Treatment Facilities for 2015. This directory is a listing of Federal, State, and local government facilities and private facilities that provide mental health treatment services. It includes treatment facilities that responded to the 2014 National Mental Health Services Survey (N-MHSS). The information about each facility that appears in this Directory was provided by that facility in response to the 2014 N-MHSS. The N-MHSS is conducted annually by the Substance Abuse and Mental Health Services Administration (SAMHSA). The Directory is ordered alphabetically by State, by city within each State, and by facility name within each city. This Directory include mental health treatment facilities for all U.S. states and territories.
Results from the 2011 National Survey on Drug Use and Health: Summary of National Findings and Detailed Tables

This page presents the annual national findings report and detailed tables from the 2011 National Survey on Drug Use and Health (NSDUH). The annual national findings report and the detailed tables include national estimates of rates of initiation and use of illicit drugs (e.g., marijuana, cocaine, heroin, hallucinogens, inhalants, and the nonmedical use of prescription-type pain relievers, tranquilizers, stimulants, and sedatives), alcohol, and tobacco products and rates of driving under the influence of drugs or alcohol. The the annual national findings report and detailed tables also covers substance use treatment need/receipt and youth risk and prevention measures. Results are provided for age group, gender, pregnancy status, race/ethnicity, education level, employment status, geographic area, parole/probation status. Comparisons are made between 2011 and 2002 to 2010.
California AFCARS Assessment Review, 2014

This webpage includes the documentation from California's Adoption and Foster Care Analysis and Reporting System (AFCARS) assessment review for fiscal year 2014:

AFCARS Assessment Review Letter

AFCARS Assessment Review Report

Tab A - Detailed Findings

Findings Instructions

Section I

AFCARS Assessment Review Findings - General Requirements

Section II

AFCARS Assessment Review Findings - Foster Care and Adoption Elements

Section III

AFCARS Assessment Review Case File Findings - Foster Care and Adoption Elements

Tab B - AFCARS Improvement Plan

Improvement Plan Instructions

Section I

AFCARS Assessment Review Improvement Plan - General Requirements

Section II

AFCARS Assessment Review Improvement Plan - Foster Care and Adoption Elements

Metadata-only record linking to the original dataset. Open original dataset below.
Behavioral Risk Factor Surveillance System (BRFSS) Age-Adjusted Prevalence Data (2011 to present)

2011 to present. BRFSS combined land line and cell phone age-adjusted prevalence data. The BRFSS is a continuous, state-based surveillance system that collects information about modifiable risk factors for chronic diseases and other leading causes of death. 
Data will be updated annually as it becomes available.

Detailed information on sampling methodology and quality assurance can be found on the BRFSS website (http://www.cdc.gov/brfss). 
Methodology: http://www.cdc.gov/brfss/factsheets/pdf/DBS_BRFSS_survey.pdf 
Glossary: https://data.cdc.gov/Behavioral-Risk-Factors/Behavioral-Risk-Factor-Surveillance-System-BRFSS-H/iuq5-y9ct
Compound 530216: N-Acetyl-Try, TMS

Chemical compound data from PubChem database. IUPAC Name: trimethylsilyl 2-acetamido-3-(1-trimethylsilylindol-3-yl)propanoate. Molecular Formula: C19H30N2O3Si2. Molecular Weight: 390.6. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
2012 Uniform Reporting System (URS) Tables for Idaho

Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Output Tables for 2012. The Uniform Reporting System (URS) is a state and national reporting system collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.
2015 CMHS Uniform Reporting System (URS) Table for Kentucky

2015 Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Output Tables for Kentucky. The URS state reporting system is collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.
Compound 528982: 1,2-Nonadecanediol, di-TMS

Chemical compound data from PubChem database. IUPAC Name: trimethyl(1-trimethylsilyloxynonadecan-2-yloxy)silane. Molecular Formula: C25H56O2Si2. Molecular Weight: 444.9. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 530321: Hexadecanoic acid, 6-methyl-2-trimethylsilyloxy, methyl ester

Chemical compound data from PubChem database. IUPAC Name: methyl 6-methyl-2-trimethylsilyloxyhexadecanoate. Molecular Formula: C21H44O3Si. Molecular Weight: 372.7. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
The Novartis-ILAR Rheumatology Prize 2001 Osteoarthritis: from molecule to man

During our careers, we have developed new and innovative concepts pertaining to the pathophysiology of osteoarthritis which have assisted in the development of new therapeutic approaches. Moreover, our laboratory has long sought to develop protective agents for osteoarthritic structural joint tissues. The most significant concepts that have originated from our lab are briefly outlined in this commentary.
Comparison of APACHE II, MEES and Glasgow Coma Scale in patients with nontraumatic coma for prediction of mortality

Introduction:
          There are numerous prehosital descriptive scoring systems, and it is uncertain whether they are efficient in assessing of the severity of illness and whether they have a prognostic role in the estimation of the illness outcome (in comparison with that of the prognostic scoring system Acute Physiology and Chronic Health Evaluation [APACHE] II). The purpose of the present study was to assess the value of the various scoring systems in predicting outcome in nontraumatic coma patients and to evaluate the importance of mental status measurement in relation to outcome.
        
        
          Patients and methods:
          In a prehospital setting, postintervention values of the Mainz Emergency Evaluation System (MEES) and Glasgow Coma Scale (GCS) were measured for each patient. The APACHE II score was recorded on the day of admission to the hospital. This study was undertaken over a 2-year period (from January 1996 to October 1998), and included 286 consecutive patients (168 men, 118 women) who were hospitalized for nontraumatic coma. Patients younger than 16 years were not included. Their age varied from 16 to 87 years, with mean ± standard deviation of 51.8 ± 16.9 years. Sensitivity, specificity and correct prediction of outcome were measured using the χ2 method, with four severity scores. The best cutoff point in each scoring system was determined using the Youden index. The difference in Youden index was calculated using the Z score. For each score, the receiver operating characteristic (ROC) curve was obtained. The difference in ROC was calculated using the Z score. P < 0.05 was considered statistically significant.
        
        
          Results:
          For prediction of mortality, the best cutoff points were 19 for APACHE II, 18 for MEES and 5 for GCS. The best cutoffs for the Youden index were 0.63 for APACHE II, 0.61 for MEES and 0.65 for GCS. The correct prediction of outcome was achieved in 79.9% for APACHE II, 78.3% for MEES and 81.9% for GCS. The area under the ROC curve (mean ± standard error) was 0.86 ± 0.02 for APACHE II, 0.84 ± 0.06 for MEES and 0.88 ± 0.03 for GCS. There were no statistically significant differences among APACHE II, MEES and GCS scores in terms of correct prediction of outcome, Youden index or area under ROC curve.
        
        
          Conclusions:
          APACHE II is not much better than prehospital descriptive scoring systems (MEES and GCS). APACHE II and MEES should not replace GCS in assessment of illness severity or in prediction of mortality in nontraumatic coma. For the assessment of mortality, the GCS score provides the best indicator for these patients (simplicity, less time-consuming and effective in an emergency situation.
Patent AT-E399843-T1: [Translated] BINDER FOR SOLIDIFICATION MATRIX

Material, composition, and manufacturing method alternatives for a solidification matrix that may be used, for example, in solid cleaning compositions, or other technologies. In at least some embodiments, the solidification matrix includes a binding agent that is formed by the use of hydroxyethylethylenediaminetriacetic acid (HEDTA), or a derivative thereof, and water to produce a solid binding agent. In some embodiments, the HEDTA and water combines and can solidify to act as a binder material or binding agent dispersed throughout a solid composition that may contain other functional ingredients that provide the desired properties and/or functionality to the solid composition.
Compound 529181: 1-Propanamine, mono-TMS

Chemical compound data from PubChem database. IUPAC Name: N-trimethylsilylpropan-1-amine. Molecular Formula: C6H17NSi. Molecular Weight: 131.29. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.